31st Mar 2025 7:05 am |
RNS |
Calquence recommended for EU approval in 1L MCL |
31st Mar 2025 7:00 am |
RNS |
Imfinzi approved in the US for bladder cancer |
21st Mar 2025 10:58 am |
RNS |
AZN invests $2.5bn in Beijing R&D & manufacturing |
17th Mar 2025 7:10 am |
RNS |
Eneboparatide Phase III trial met primary endpoint |
17th Mar 2025 7:05 am |
RNS |
Imfinzi approved in EU for limited-stage SCLC |
17th Mar 2025 7:00 am |
RNS |
AstraZeneca to acquire EsoBiotec |
12th Mar 2025 6:00 pm |
RNS |
Holding(s) in Company |
7th Mar 2025 3:00 pm |
RNS |
Director/PDMR Shareholding |
7th Mar 2025 11:00 am |
RNS |
Notice of AGM |
7th Mar 2025 7:00 am |
RNS |
Imfinzi improved EFS in early-stage gastric cancer |
6th Mar 2025 3:00 pm |
RNS |
Director/PDMR Shareholding |
5th Mar 2025 3:00 pm |
RNS |
Director/PDMR Shareholding |
3rd Mar 2025 3:00 pm |
RNS |
Total Voting Rights |
3rd Mar 2025 7:00 am |
RNS |
Imfinzi recommended for EU approval for AEGEAN |
28th Feb 2025 1:00 pm |
RNS |
Enhertu recommended in EU in post-ET breast cancer |
26th Feb 2025 7:00 am |
RNS |
Camizestrant improved PFS in 1L HR+ breast cancer |
19th Feb 2025 7:00 am |
RNS |
Filing of Form 20-F with SEC |
18th Feb 2025 2:00 pm |
RNS |
Holding(s) in Company |
18th Feb 2025 11:00 am |
RNS |
Annual Financial Report |
18th Feb 2025 7:00 am |
RNS |
Directorate Change |
6th Feb 2025 7:00 am |
RNS |
Final Results |
3rd Feb 2025 5:00 pm |
RNS |
Total Voting Rights |
3rd Feb 2025 7:00 am |
RNS |
Imfinzi recommended for EU approval for LS-SCLC |
28th Jan 2025 7:00 am |
RNS |
Enhertu approved in US for breast cancer post ET |
20th Jan 2025 7:00 am |
RNS |
Dato-DXd approved in US for HR+ breast cancer |
17th Jan 2025 7:00 am |
RNS |
Calquence combination approved in US for 1L MCL |
2nd Jan 2025 3:00 pm |
RNS |
Total Voting Rights |
24th Dec 2024 7:00 am |
RNS |
Dato-DXd NSQ NSCLC application withdrawn in EU |
23rd Dec 2024 7:00 am |
RNS |
Tagrisso approved in EU based on LAURA trial |
16th Dec 2024 7:00 am |
RNS |
Directorate Change |
5th Dec 2024 7:00 am |
RNS |
Imfinzi approved in US for limited-stage SCLC |
4th Dec 2024 1:45 pm |
RNS |
AstraZeneca appoints Iskra Reic EVP International |
2nd Dec 2024 3:05 pm |
RNS |
Block listing Interim Review |
2nd Dec 2024 3:00 pm |
RNS |
Total Voting Rights |
25th Nov 2024 7:00 am |
RNS |
Truqap improved rPFS in advanced prostate cancer |
20th Nov 2024 4:00 pm |
RNS |
Director/PDMR Shareholding |
18th Nov 2024 7:00 am |
RNS |
Tagrisso recommended for EU approval - LAURA |
15th Nov 2024 2:00 pm |
RNS |
Director/PDMR Shareholding |
15th Nov 2024 10:00 am |
RNS |
Director/PDMR Shareholding |
13th Nov 2024 4:00 pm |
RNS |
Director/PDMR Shareholding |